PM14

Phase 2Small molecule

PPharmaMar

PM14 is one of 89 small molecule programs targeting Patients With Advanced Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Patients With Advanced Solid TumorsRecruiting

Soft Tissue SarcomaRecruiting

Patients With Advanced Solid TumorsPhase 1

Recruiting

Soft Tissue SarcomaPhase 2

Recruiting

Competition

Competitive Landscape

249 competitors in Patients With Advanced Solid Tumors

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 2

10 2

Avastin

Roche

Phase 2

10 3

Eloxatin

Teva

Phase 2

9 4

Opdivo

Bristol-Myers Squibb

Phase 2

9 5

Paraplatin

AAvyxa

Phase 2

22 6

Lynparza

AstraZeneca

Phase 2

5 7

Camptosar

Pfizer

Phase 2

4 8

Yervoy

Bristol-Myers Squibb

Phase 2

4 9

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Imfinzi

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

PM14 Administered Intravenously to Patients with Advanced Solid Tumors

Recruiting·PPharmaMar·Phase 1·NCT05076396·150 enrolled

Soft Tissue Sarcoma1 trial

Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor

Recruiting·GGrupo Espanol de Investigacion en Sarcomas·Phase 1/2·NCT05146440·195 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PM14. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PM14 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PM14. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — PharmaMar company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPharmaMar

PM14

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

Soft Tissue Sarcoma1 trial

References

Drug Info

Quick Facts

Related News